Cabaletta Bio Q3 2020 Earnings Report
Key Takeaways
Cabaletta Bio reported its Q3 2020 financial results, highlighting the ongoing patient enrollment for the DSG3-CAART program and the anticipation of acute safety data in the first half of 2021. The company's cash and investments are expected to fund operations through at least Q3 2022.
Patient enrollment is underway for the lead program, DSG3-CAART, targeting mucosal pemphigus vulgaris.
Acute safety data from the first cohort of patients in the DSG3-CAART trial is expected in the first half of 2021.
Comprehensive preclinical data for DSG3-CAART was published in The Journal of Clinical Investigation, validating its mechanism of action.
IND-enabling studies are ongoing for MuSK-CAART, with an IND submission to the FDA anticipated in the second half of 2021.
Cabaletta Bio
Cabaletta Bio
Forward Guidance
Cabaletta Bio expects that its cash and cash equivalents and investments as of September 30, 2020 will enable it to fund its operating plan through at least the third quarter of 2022.